@article {1301, title = {Immunosuppressive Activity of Goat Kefir in a Rat Model with Bleomycin-induced Pulmonary Fibrosis}, journal = {Pharmacognosy Journal}, volume = {12}, year = {2020}, month = {November 2020}, pages = {1594-1599}, type = {Research Article}, chapter = {1594}, abstract = {

Objective: This study aimed to investigate the immunomodulatory capacity of goat kefir on pulmonary fibrosis rat model. Material and Methods: Twenty-five male rats were randomly divided into five groups: one group only received induction with bleomycin (0.3 mg/rat) to induce pulmonary fibrosis; three groups were treated with different doses (2.5, 3.5, and 4.5 mL/200 g BW) of goat kefir, following the induction with bleomycin, for 30 days; and one group served as negative control, did not receive bleomycin induction as well as kefir. On day 30, all the animals were sacrificed. Plasma levels of TGF-β, IL-4, and IFN-y were measured using the ELISA method, and the expression of α-SMA in myofibroblast cells was examined with the help of immunohistochemistry assay. Results: Induction with bleomycin significantly elevated the expressions of TGF-β, IL-4, and IFN-y in comparison to the control group. Following the administration of kefir (3.5 and 4.5 mL/200 g BW), the concentration of TGF-β was significantly decreased (p\<0.05); whereas, the concentration of IFN-y increased slightly (p\<0.05) only in the group that received the 4.5 mL/200 g BW dose of kefir. In contrast, IL-4 exhibited increasing levels with higher doses of kefir (p\<0.05). The expression of α-SMA in myofibroblasts showed a tendency to decline following the administration of kefir, although this decline was not statistically significant. Conclusions: Goat kefir caused a reduction in the TGF-β levels in fibrosis conditions; however, the kefir elicited an immunosuppressive effect during the progression of the pulmonary fibrosis.

}, keywords = {Bleomycin, Cytokine, Immunomodulator, Kefir, Pulmonary fibrosis}, doi = {10.5530/pj.2020.12.218}, author = {Tias Pramesti Griana and Tri Yudani Mardining Raras and Karyono Mintaroem and Iin Noor Chozin and Catur Saptaning Wilujeng} } @article {1239, title = {In vitro Assay and Study Interaction of Uncaria gambir (Hunter) Roxb. as Anti-fibrotic Activity Against A549 Cell Line}, journal = {Pharmacognosy Journal}, volume = {12}, year = {2020}, month = {September 2020}, pages = {1232-1240}, type = {Original Article}, chapter = {1232}, abstract = {

Aim: The aim of this study is to finding inhibitor potential from several compounds in gambir plant by using in vitro MTT assay and study interaction with molecular docking. The interaction of amino acids on the binding site with substances in the gambir plant was analyzed to determine its potential as a herbal-based therapy candidate for pulmonary fibrosis. Material and Methods: Protein target using TGFβ1 and NF-κB and compounds from gambir plant ((+)-Catechin. Epigallocatechin gallate, (+)-Epicatechin, Gambiriin A1, Gambiriin A2, Gambiriin B1, Gambiriin B2, Gambiriin C, Procyanidin B1, Procyanidin B3). Result: The results from docking analysis observed that compounds from gambir fruit contain anti-fibrotic activity which act by inhibiting DNA transcription of NF-κB and TGF-β1receptors. The compound Procyanidin B3, an essential amino acid, contains a hydrogen bond with the greatest NF-κB inhibitory activity on Gly214 and Lys337. Compounds from Uncaria gambir (Hunter) Roxb. can be an inhibitor to TGFβ1, all the compounds are on the active site of TGFβ1, and use native ligand which is an inhibitor of TGFβ1 (Naphtyridine). The positive compound catechin has the highest inhibitory activity. Gambiriin B1 and Gambiriin A2 are the most identical compounds with similar affinity binding value. Uncaria gambir (Hunter) Roxb. is already a proven antifibrotic which is further confirmed by (IC50: 19,255 {\textpm} 1.08 μg/ml, p \< 0.05) in A549 cell line. Conclusion: The results demonstrated that Gambiriin have cytotoxic effects and was found potentially as anti-fibrotic by MTT assay and in silico evaluation.

}, keywords = {Gambiriin compounds, Inhibitor of p50 NF-κB, Molecular docking, Pulmonary fibrosis, TGF-β1 receptors}, doi = {10.5530/pj.2020.12.172}, author = {Desdiani Desdiani and Iris Rengganis and Samsuridjal Djauzi and Agus Setiyono and Mohamad Sadikin and Sri Widia A Jusman and Nuryati Chairani Siregar and Suradi and Putri C Eyanoer and Fadilah Fadilah} }